Literature DB >> 7520347

Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas.

M G Huisse1, M Leclercq, J Belghiti, J F Flejou, J W Suttie, A Bezeaud, D W Stafford, M C Guillin.   

Abstract

BACKGROUND: An important marker for hepatocellular carcinoma is the presence of des-gamma-carboxy (abnormal) prothrombin. However, the molecular basis for the reduced carboxylation of prothrombin is unknown.
METHODS: Two groups of patients were defined according to the absence (Group I, n = 7) or presence (Group II, n = 8) of des-gamma-carboxy prothrombin. The enzymatic activity of gamma-carboxylase and the total microsomal prothrombin concentration were determined in all tumors. The kinetic parameters for the synthetic peptide Phe-Leu-Glu-Glu-Leu (FLEEL) were measured in eight tumors. The gamma-carboxylase mRNA expression was evaluated by Northern blot analysis in 12 of 15 tumors. In addition, the total vitamin K content (K1, K1 epoxide, and menaquinones 4-10) in 10 tumors was investigated by high performance liquid chromatography.
RESULTS: Concentrations of menaquinones 4-10 were normal in the nontumorous part of the liver but significantly decreased (P = 0.02) in all the tumors (Groups I and II). This decrease was more severe in Group II (P = 0.02). The tumors in Group I had normal or increased gamma-carboxylase activity and increased mRNA expression (P < 0.02) as compared with their nontumorous counterparts. The tumors in Group II were heterogeneous. Five tumors displayed low gamma-carboxylase activity, associated with low mRNA expression in two, whereas two others had high gamma-carboxylase activity and mRNA expression. The concentration of FLEEL at half-maximal velocity was normal in all the tumors examined (Groups I and II), and a relation was found between the level of expression of gamma-carboxylase and the maximal velocity for FLEEL carboxylation in the tumors in Group II (r = 0.98; P < 0.01). The microsomal content of normal prothrombin was within normal limits in all tumors (Groups I and II).
CONCLUSIONS: Tumor vitamin K content has a critical role in the synthesis of des-gamma-carboxy prothrombin. Furthermore, the gamma-carboxylase defect, which is observed in some secreting tumors, is the result of the defective gene expression of a normal enzyme and not the consequence of the presence of a competitive inhibitor. It is possible that a 75% reduction in gamma-carboxylase gene expression could take a part in the secretion of des-gamma-carboxy prothrombin, but this mechanism is not predominant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520347     DOI: 10.1002/1097-0142(19940901)74:5<1533::aid-cncr2820740507>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Protein induced by vitamin K absence or antagonist II-producing gastric cancer.

Authors:  Yoshihisa Takahashi; Tohru Inoue; Toshio Fukusato
Journal:  World J Gastrointest Pathophysiol       Date:  2010-10-15

2.  Growth inhibitory actions of prothrombin on normal hepatocytes: influence of matrix.

Authors:  Brian I Carr; Siddhartha Kar; Meifang Wang; Ziqiu Wang
Journal:  Cell Biol Int       Date:  2007-03-19       Impact factor: 3.612

3.  Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.

Authors:  Naoki Ueda; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Yutaka Nakanishi; Mayumi Suzuki; Noriyuki Matsuo; Shigetomi Tanaka; Shin-Ichi Nishina; Masayuki Uemura; Akinobu Takaki; Yasushi Shiratori; Kazuhide Yamamoto
Journal:  Mol Oncol       Date:  2008-06-20       Impact factor: 6.603

4.  Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images.

Authors:  Azusa Kitao; Osamu Matsui; Norihide Yoneda; Kazuto Kozaka; Satoshi Kobayashi; Wataru Koda; Toshifumi Gabata; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma; Ryuichi Kita; Shigeki Arii
Journal:  Radiology       Date:  2012-12       Impact factor: 11.105

5.  Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP).

Authors:  Kazuhiro Matsueda; Hiroshi Yamamoto; Yasuo Yoshida; Kenji Notohara
Journal:  J Gastroenterol       Date:  2006-11-09       Impact factor: 6.772

6.  Primary colon cancer with a high serum PIVKA-II level.

Authors:  Kazuya Kato; Yoshiaki Iwasaki; Masahiko Taniguchi; Kazuhiko Onodera; Minoru Matsuda; Takako Kawakami; Mineko Higuchi; Kimitaka Kato; Yurina Kato; Hiroyuki Furukawa
Journal:  Int J Surg Case Rep       Date:  2014-12-04

Review 7.  Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent.

Authors:  Munechika Enjoji; Daisuke Watase; Kazuhisa Matsunaga; Mariko Kusuda; Nami Nagata-Akaho; Yoshiharu Karube; Jiro Takata
Journal:  Diseases       Date:  2015-07-22

8.  Vitamin K contents in liver tissue of hepatocellular carcinoma patients.

Authors:  T Miyakawa; Y Kajiwara; A Shirahata; K Okamoto; H Itoh; K Ohsato
Journal:  Jpn J Cancer Res       Date:  2000-01

9.  Gla-rich protein is a potential new vitamin K target in cancer: evidences for a direct GRP-mineral interaction.

Authors:  Carla S B Viegas; Marjolein Herfs; Marta S Rafael; José L Enriquez; Alexandra Teixeira; Inês M Luís; Cynthia M R van 't Hoofd; Alexandre João; Vera L Maria; Sofia Cavaco; Ana Ferreira; Manuel Serra; Elke Theuwissen; Cees Vermeer; Dina C Simes
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

10.  Antitumor Effects and Delivery Profiles of Menahydroquinone-4 Prodrugs with Ionic or Nonionic Promoiety to Hepatocellular Carcinoma Cells.

Authors:  Shuichi Setoguchi; Daisuke Watase; Kazuhisa Matsunaga; Hirofumi Yamakawa; Shotaro Goto; Kazuki Terada; Kenji Ohe; Munechika Enjoji; Yoshiharu Karube; Jiro Takata
Journal:  Molecules       Date:  2018-07-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.